Topical Terbinafine Safety in Children
Topical terbinafine 1% cream is safe and effective for use in children aged 2 years and older for superficial dermatophyte infections of the skin, though the FDA label specifically states "do not use on nails or scalp" for over-the-counter formulations. 1
Key Safety Evidence
The safety profile of topical terbinafine in children is well-established:
In a study of 97 children aged 2-15 years with tinea corporis/cruris treated with terbinafine 1% cream once daily for 1 week, adverse reactions were minimal: itching (3%), itching with erythema (1%), and contact dermatitis (1%). The treatment was considered effective in 92% of patients. 2
Comprehensive pediatric experience across six clinical studies involving 196 children (ages 2-17 years) demonstrated that terbinafine was very well tolerated, with cure rates exceeding 90% for various dermatophyte skin infections. 3
A pilot study using 1% encapsulated terbinafine gel on the scalp of 10 children (mean age 10.3 years) reported no significant side effects, though this contradicts FDA labeling for OTC products. 4
Important Caveats and Limitations
FDA labeling restrictions are critical: The over-the-counter formulation explicitly warns "do not use on nails or scalp" 1, which creates a discrepancy with some clinical research showing efficacy for scalp infections.
For tinea capitis specifically: British Association of Dermatologists guidelines emphasize that topical therapy alone is NOT recommended—oral therapy is required for clinical and mycological cure. 5 This is because topical agents cannot adequately penetrate hair follicles where dermatophytes reside.
Clinical Application Algorithm
For children ≥2 years with superficial skin infections:
- Tinea corporis/cruris: Topical terbinafine 1% cream applied once or twice daily for 1-2 weeks is safe and highly effective (>90% cure rates) 2, 6
- Tinea pedis: Same regimen, with mycological cure rates >80% 6, 7
Avoid topical terbinafine for:
- Tinea capitis (requires oral therapy) 5
- Nail infections (requires oral therapy) 1
- Children under 2 years (insufficient safety data for topical formulations)
Monitor for: Local irritation, itching, or contact dermatitis (occurs in <5% of pediatric patients) 2
The evidence strongly supports that topical terbinafine is one of the safest and most effective antifungal options for treating superficial dermatophyte infections in children aged 2 years and older, with a superior safety profile compared to many alternatives and requiring shorter treatment duration than older agents like clotrimazole. 7